CSANZ-Boehringer Ingelheim Cardiovascular Research Innovation Grants

Call  for  Applications

Applications are now open for the CSANZ-Boehringer Ingelheim Cardiovascular Research Innovation Grants, exclusively supported by an unrestricted research grant from Boehringer Ingelheim. The grants aim to stimulate innovative and ground-breaking research in cardiovascular medicine by early career researchers.

Two grants of up to $50,000 each are available

Both interventional and observational studies (in animal models or in humans) within the following fields will be considered:

  • Thromboembolic Disease (general)
  • Atrial Fibrillation
  • Stroke
  • Deep Vein Thrombosis / Pulmonary Embolism
  • Percutaneous Coronary Intervention
  • Coronary Artery Disease and / or Peripheral Artery Disease

Applications seeking to investigate Non Vitamin K Oral Anticoagulants (NOACs) must include more than one NOAC.

Out-of-scope of the grants are:

  • studies replicating findings of completed Phase IV or on-going large scale clinical trials (statistically powered)
  • studies evaluating off-label indications/use of a study drug(s)
  • studies under review/currently funded by any industry grants

Eligible applicants must be:

  • no more than six years post-award of PhD or postgraduate qualification
  • domiciled in Australia or New Zealand
  • affiliated with an academic/scientific institution or national health care system

The research project must have publishable data/outcomes within 18 to 24 months from award.

All applications will be reviewed by the CSANZ Scientific Committee.

Download Grant Conditions

Application  Requirements

  • Completed application form (click here to download)
  • Two-page Current CV
  • List of publications in the last six years
  • 1500 word Research Project Outline
  • Letter of support from Supervisor
  • Clearance documents declared at Item 6 in the application form


For further information contact the CSANZ on email: info@csanz.edu.au or phone +61 2 9226 7900.